Gilead Sciences, Inc. (GILD), headquartered in Foster City, California, is a biopharmaceutical company that discovers, ...
Gilead Sciences Inc. stock reached an all-time high of 128.71 USD, marking a significant milestone for the biopharmaceutical company. According to InvestingPro data, the stock is trading just 0.99% ...
Gilead Sciences recently reported in The New England Journal of Medicine that its Phase 3 ASCENT-04/KEYNOTE-D19 trial showed Trodelvy plus Keytruda improved progression-free survival over Keytruda ...
Gilead Sciences, Inc. (NASDAQ:GILD) is among the most profitable healthcare stocks to buy. On January 26, UBS lifted the ...
Gilead Sciences is undervalued, with a Buy rating and a DCF-based target price of $141, implying 13.4% upside. Click here to ...
Gilead Sciences (NasdaqGS:GILD) reported positive Phase 3 ASCENT-04/KEYNOTE-D19 results for Trodelvy plus Keytruda in ...
Zacks.com on MSN
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
Gilead Sciences (GILD) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...
Gilead's Q3 results exceeded expectations, with EPS of $2.47 and revenue of $7.8 billion, driven by HIV franchise outperformance. Learn more about GILD stock here.
Investors in Gilead Sciences Inc (Symbol: GILD) saw new options become available today, for the January 2026 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ...
Gilead Sciences (NASDAQ:GILD) announced its second-quarter 2025 earnings and revised annual outlook after the market closed on Thursday. The HIV drug maker reported adjusted earnings of $2.01 per ...
Ten months later, Gilead's stock price had fallen into the $70s. The HIV business was doing even better than expected, prompting Katsenelson to switch lenses and argue that $70 a share was a fair ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results